Paul E. Sax - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Paul E. Sax's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Paul E. Sax
Verified
Contributing Editor, NEJM Journal Watch
Boston
Beats
COVID Pediatrics , Health , Medical News , Science , Innovation , Primary Care , Women’s Health , Men’s Health
Nothing MLM. Unfunded Startups.
Content
By Paul E. Sax| NEJM Journal Watch Verified Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising "bug-drug" studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, everyone associates "chemotherapy" with cancer treatment, which of course this wasn't.
By Paul E. Sax| NEJM Journal Watch Verified Imagine you're birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly:Look, it's the elusive Blujepa! A rare sighting!No, not a real bird, but Blujepa is the brand name of gepotidacin, something rarer - and arguably more exciting - than a tropical bird, at least to us ID geeks: a brand new antibiotic class for treatment of uncomplicated urinary tract infections.
By Paul E. Sax| NEJM Journal Watch Verified Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising "bug-drug" studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, everyone associates "chemotherapy" with cancer treatment, which of course this wasn't.
Company Info
NEJM Journal Watch